| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
This compound does not have a defined pharmacological target in biological systems, as it is primarily a chemical reagent and synthetic intermediate with no therapeutic applications. However, triphenylmethanol has been shown to inhibit neoplastic transformation of cells, suggesting potential antiproliferative properties. Its mechanism of action in this context is not well understood but may relate to its ability to act as a specific clathrate host for methanol and dimethyl sulfoxide (DMSO) and to form molecular complexes with various small molecules. The triphenylmethyl (trityl) carbocation is a stable, resonance-stabilized species that can participate in various chemical reactions, but this chemistry does not translate directly to defined biological targets.
|
|---|---|
| ln Vitro |
In vitro, triphenylmethanol has been shown to inhibit neoplastic transformation of cells, indicating antiproliferative activity. While the precise IC₅0 values are not widely reported in the literature, the compound has been studied for its ability to prevent the transformation of normal cells into tumor cells in culture-based transformation assays. In standard proliferation assays using cancer cell lines, triphenylmethanol and its derivatives have demonstrated moderate cytotoxic effects. The compound also exhibits the ability to form inclusion complexes (clathrates) with small guest molecules such as methanol and DMSO, which can be exploited for separation and purification applications in analytical chemistry.
|
| ln Vivo |
In vivo activity of triphenylmethanol has not been extensively characterized, as it is not a drug candidate. The compound is primarily used as a chemical reagent and synthetic intermediate rather than for therapeutic evaluation in animal models. Triphenylmethanol is known to be a combustion hazard (combustible solid) and may release irritating and toxic fumes (carbon monoxide, carbon dioxide) upon decomposition under fire conditions. It has no known therapeutic applications in animals or humans. The compound is not intended for in vivo administration in any medical context.
|
| Enzyme Assay |
Non-cellular (cell-free) experiments with triphenylmethanol are primarily chemical in nature. A typical protocol for using triphenylmethanol as a clathrate host for methanol separation involves dissolving triphenylmethanol in a suitable organic solvent and crystallizing it in the presence of methanol, where it forms a 1:1 inclusion complex. For analytical purposes, HPLC methods for monitoring triphenylmethanol content use a C18 reverse-phase column with a mobile phase of acetonitrile and water (70:30 v/v) at a flow rate of 1.0 mL/min, with UV detection at 254 nm. The compound is soluble in alcohol, ether, and benzene, but is insoluble in water.
|
| Cell Assay |
Cell-based experiments for triphenylmethanol are typically conducted to evaluate its antiproliferative and anti-neoplastic transformation properties. A standard protocol for transformation assays uses mouse C3H10T1/2 fibroblasts (an embryonic mesenchymal cell line). Cells are seeded at low density in 6-well plates and cultured in DMEM supplemented with 10% fetal bovine serum. The following day, cells are treated with triphenylmethanol at concentrations ranging from 1 to 100 microM, with or without exposure to a chemical carcinogen (e.g., 3-methylcholanthrene). After 5-7 days, cells are fixed with methanol, stained with Giemsa stain, and transformed foci are scored under an inverted microscope. The number of Type II and Type III foci is counted, representing the extent of neoplastic transformation inhibition. For viability assessment, MTT assays can be performed.
|
| Animal Protocol |
In vivo animal experiments are not typically conducted for triphenylmethanol, as it is a research chemical with no therapeutic indication. However, toxicological evaluations may be performed for safety assessment. A standard acute oral toxicity study in Sprague-Dawley rats would involve a single oral gavage dose of triphenylmethanol (e.g., 500, 1000, 2000 mg/kg) suspended in corn oil or 0.5% methylcellulose. Animals are observed for 14 days for signs of toxicity, mortality, and body weight changes. At study termination, necropsy is performed, and organs (liver, kidneys, heart, lungs, spleen) are examined for gross abnormalities. Histopathological examination may be conducted. Triphenylmethanol may cause irritation of the digestive tract and respiratory tract irritation upon inhalation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of triphenylmethanol are not well characterized, as it is a chemical reagent rather than a drug candidate. Based on its physicochemical properties (logP approximately 4-5, molecular weight 260.33), it is a lipophilic compound that would be expected to undergo extensive metabolism by cytochrome P450 enzymes if absorbed. The compound is practically insoluble in water (solubility <0.01 mg/mL) but soluble in organic solvents such as ethanol, diethyl ether, benzene, and acetone. It is stable under normal laboratory conditions (room temperature, inert atmosphere) but sensitive to strong oxidizing agents, strong acids, and light. When dissolved in concentrated sulfuric acid, it turns dark yellow, while it remains colorless when dissolved in glacial acetic acid.
|
| Toxicity/Toxicokinetics |
The toxicological properties of triphenylmethanol have not been fully investigated. Available GHS hazard classifications indicate that triphenylmethanol causes skin irritation (H315) with >98% of notifications reporting this hazard. It may cause serious eye irritation (H319) and may cause respiratory tract irritation (H335) (Specific Target Organ Toxicity, single exposure, Category 3). Acute oral toxicity data are not available. Chronic effects may include dermatitis and asthma-like symptoms upon prolonged or repeated exposure. As a combustible solid, it should be kept away from sources of ignition. The compound has a water hazard class (WGK) of 3, indicating it is hazardous to water. Decomposition products upon combustion include carbon monoxide, carbon dioxide, and irritating and toxic fumes and gases.
|
| References |
|
| Additional Infomation |
Additional information: Triphenylmethanol is a white powder or colorless isolated crystals with a density of 1.199 at 40degC (d40). Its IUPAC name is triphenylmethanol. It has an EC number of 200-988-5 and RTECS number of DC1850000. The compound is soluble in alcohol, ether, benzene, and glacial acetic acid, and insoluble in water and petroleum ether. It is stable under normal temperatures and pressures but is incompatible with oxidizing agents, acids, acid chlorides, and acid anhydrides. Triphenylmethanol is frequently employed as a reactant in the formation of esters, ethers, and other functionalized compounds through various chemical transformations including esterification and Grignard reactions. It is a versatile compound used in organic synthesis as a protecting group reagent (trityl chloride is derived from triphenylmethanol) and as a standard for chromatographic analysis.
|
| Molecular Formula |
C19H16O
|
|---|---|
| Molecular Weight |
260.34
|
| Exact Mass |
260.12
|
| CAS # |
76-84-6
|
| PubChem CID |
6457
|
| Appearance |
Typically exists as solids at room temperature
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
235
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)O
|
| InChi Key |
LZTRCELOJRDYMQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H16O/c20-19(16-10-4-1-5-11-16,17-12-6-2-7-13-17)18-14-8-3-9-15-18/h1-15,20H
|
| Chemical Name |
triphenylmethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8411 mL | 19.2057 mL | 38.4113 mL | |
| 5 mM | 0.7682 mL | 3.8411 mL | 7.6823 mL | |
| 10 mM | 0.3841 mL | 1.9206 mL | 3.8411 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
